HCG has been at the forefront of cancer care, pioneering innovative approaches that integrate multi-disciplinary expertise, advanced molecular and genetic diagnostics, and a hub- and-spoke patient outreach model. These efforts enable us to deliver highly personalized care, and our strong performance stands as a testament to these strategies. Guided by our vision of making cancer care accessible and affordable, we are committed to reaching over 50% of cancer patients in India through our unique hub-and-spoke model. In addition to our existing Centers of Excellence in Bangalore, Mumbai, Ahmedabad, and Kolkata, we are expanding our footprint by establishing multiple CoEs in Cuttack and Odisha.

We are proud to announce highest ever quarterly revenues of Rs 558 crores with a robust growth of 19% and EBITDA standing at Rs 87 crores with a growth of 11% compared to same period last year. Despite being a seasonally weaker quarter, we are proud to have achieved this performance on the basis of improving volumes across modalities. The Oncology business post MG hospital acquisition grew by 24%. Our emerging centers continue to perform well, Kolkata center grew by 40% and South Bombay center grew by 28%. South Bombay center witnessed strong performance despite challenges in international business, which we expect to recover by the upcoming quarter and will be key for the center’s turnaround. We are confident of the robust growth in these centers with improving performance on the back of strong brand creation, quality clinical talent and increased awareness programs for cancer care and diagnosis.